Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262164 | 0.87 | CYP2A13 (0.54) | CYP2A13CYP2C9ALOX15HSD17B10CNR2 | |
| SCHEMBL27828920 | 0.86 | CYP2A13 (0.52) | CYP2A13CYP2C9ALOX15HSD17B10CNR2 | |
| SCHEMBL12451266 | 0.84 | CYP2A13 (0.54) | CYP2A13CYP2C9ALOX15HSD17B10CNR2 | |
| SCHEMBL16380755 | 0.84 | KMT2A (0.54) | ALDH1A1KDM4EMAPK1L3MBTL1MAPT | |
| SCHEMBL1012433 | 0.82 | L3MBTL1 (0.60) | CYP2C9ALOX15HSD17B10ALDH1A1KDM4E | |
| SCHEMBL11621223 | 0.82 | ALDH1A1 (0.50) | CYP2A13CYP2C9ALOX15HSD17B10CNR2 | |
| SCHEMBL10207665 | 0.81 | KMT2A (0.58) | CNR2ALDH1A1POLBMAPK1CNR1 | |
| SCHEMBL12412597 | 0.81 | PDE3B (0.50) | CYP2C9ALOX15HSD17B10CNR2ALDH1A1 | |
| SCHEMBL1014280 | 0.81 | CYP2A13 (0.47) | CYP2A13CYP2C9ALOX15HSD17B10CNR2 | |
| Hydrochloric Acid SCHEMBL11625902 | 0.81 | L3MBTL1 (0.51) | CYP2A13CYP2C9ALOX15HSD17B10CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2272835-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009131171-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | 大日本住友製薬株式会社 (JP) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | CCL11, CCR1, CCR10 | CYP2A13 929/4885CYP2C9 1254/4885ALOX15 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.